Publication: 3045

Publication: 3045

Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Cancer vol 125 (19) 3378-3389

Year:: 2019
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 9

Parents:: 2766
Children:: None

Program:: OGC
Primary Committee:: Lymphoma
Sec. Committees:

Pharmas:: GSK (Novartis)
Grants:: U10CA180821, U10CA180882, U10CA180833, U10CA180850, UG1CA189858

Corr. Author:
Authors:: Kristie A. Blum Mei-Yin Polley Sin-Ho Jung Travis J. Dockter Sarah Anderson Eric D. Hsi Nina Wagner-Johnston Beth Christian Jim Atkins Bruce D. Cheson John P. Leonard Nancy L. Bartlett

Networks:: CAPITAL, LAPS-MD017, LAPS-MN026, LAPS-MO011, LAPS-OH007, NC002, NY018

Study: CALGB-50904
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Ofatumumab, bendamustine, bortezomib, follicular lymphoma